Tatva Chintan Pharma nosedives ~8% post Q4FY22 numbers

26 Apr 2022 , 11:53 AM

Tatva Chintan Pharma Limited’s counter tumbled near 8% as the company disclosed its results for the quarter and financial year ended March 31, 2022.

Tatva Chintan logged a decline of 17.09% in PAT for Q4FY22 at Rs17.50 crore as compared to Rs21.12 crore in Q4FY21. Whilst PBT dipped 21.71% yoy at Rs18.98 crore in Q4FY22 as compared to Rs24.24 crore in Q4FY21.

Its PAT for FY22 jumped 83.45% yoy at Rs95.87 crore as compared to Rs52.26 crore in FY21.

It reported a decline of 9.33% yoy in Revenue from operations at Rs98.53 crore in Q4FY22 as against Rs108.67 crore in Q4FY21. However, Revenue from operations during FY22 jumped 44.38% yoy at Rs433.65 crore as compared to Rs300.36 crore in FY21.

The company’s EBITDA for the quarter under review slipped 17.57% yoy at Rs22.31 crore against Rs27.06 crore in Q4FY21. Whereas, EBITDA for the financial year as a whole gained 63.51% yoy at Rs117.13 crore as compared to Rs71.64 crore in the previous financial year.

EBITDA margin and PAT margin for the financial year stood at 27.01% and 22.11% respectively.

Tatva Chintan is currently trading at Rs2,312.20 down by Rs186.2 or 7.45% from its previous closing of Rs2,498.40 on the BSE. The scrip opened at Rs2,250 and has touched day’s high and low of Rs2,351.20 and Rs2,250 respectively so far.